Efficacy and safety of inhaled molecular hydrogen therapy in patients with respiratory failure due to chronic obstructive pulmonary disease exacerbation in post-COVID period
Authors:
Open Access
- 11 October 2024
- journal article
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 34 (5) , 655-667
Abstract
Molecular hydrogen (H2) is a powerful antioxidant and anti-apoptotic agent. H2 has been studied in a number of clinical studies in the recent years.The aim of this research was to investigate the efficacy and safety of H2 inhalation therapy in patients with hypoxemic and hypercapnic respiratory failure (RF) against exacerbation of chronic obstructive pulmonary disease (COPD) in the post-COVID (Corona Virus Disease 2019) period.Methods. The randomized prospective parallel comparative study included patients (n = 60: 40 men aged 71.2 ± 1.8 years, 20 women aged 70.9 ± 2.8 years) with a post-COVID-19 exacerbation of COPD complicated by hypoxemic/hypercapnic RF. The patients were divided into 2 groups: group 1 (main) (n = 30: 18 men, 12 women), group 2 (control) (n = 30: 18 men, 12 women). To maintain arterial blood saturation ≥ 90 %, patients in both groups received respiratory support (non-invasive ventilation) using the Prisma 25ST device (Lowenstein Medical, Germany) in the BiPAP S/T mode (BiLevel Positive Airway Pressure Spontaneous/Time spontaneous/forced mode 20–24/4–6 cm H2O and O2, respectively; the fractional oxygen concentration in the inhaled gas mixture was ≥ 24%). In addition to standard treatment, patients in the main group received additional H2 therapy (Suisonia device, Japan) through a nasal cannula for 90 minutes daily for 14 days.Results. In patients of the main group, a decrease in the stiffness index was detected from 14.6 ± 1.2 to 6.2 ± 0.6 m/s, and the arterial blood lactate level – from 2.84 ± 0.1 to 0.02 ± 0.1 mmol/l (p < 0.001), the calculated shunt fraction Qs/Qt (venous admixture) – from 27.21 ± 3.4 to 7.14 ± 1.23 (p < 0.01) and an increase in the following parameters: reflection index – from 42.2 ± 2.0 to 66.2 ± 4.9% (p < 0.05), virus-specific IgG level – from 134 ± 125 to 669 ± 164 (p < 0. 05), blood flow velocity in arterioles – from 473 ± 108 to 868 ± 64 μm/s (p < 0.05), blood flow velocity in venules – from 299 ± 56 to 862 ± 69 μm/s (p < 0.05), the 6-minute walk distance – from 57.1 ± 4.4 to 328.9 ± 33.7 m (p < 0.05).Conclusion. H2 inhalations were safe and increased the therapeutic effect when added to standard therapy for patients with hypoxemic and hypercapnic RF during exacerbation of COPD in the post-COVID period.Keywords
This publication has 37 references indexed in Scilit:
- Inhalation of water electrolysis-derived hydrogen ameliorates cerebral ischemia–reperfusion injury in rats – A possible new hydrogen resource for clinical useNeuroscience, 2016
- Hydrogen ameliorates pulmonary hypertension in rats by anti-inflammatory and antioxidant effectsThe Journal of Thoracic and Cardiovascular Surgery, 2015
- Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013The Lancet, 2015
- Oral intake of hydrogen-rich water ameliorated chlorpyrifos-induced neurotoxicity in ratsToxicology and Applied Pharmacology, 2014
- Molecular hydrogen as a preventive and therapeutic medical gas: initiation, development and potential of hydrogen medicinePharmacology & Therapeutics, 2014
- New anti-inflammatory targets for chronic obstructive pulmonary diseaseNature Reviews Drug Discovery, 2013
- Anti-inflammatory effect of hydrogen-rich saline in a rat model of regional myocardial ischemia and reperfusionInternational Journal of Cardiology, 2011
- Why Have Antioxidants Failed in Clinical Trials?The American Journal of Cardiology, 2008
- Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicalsNature Medicine, 2007
- Increased production of endogenous nitric oxide in patients with bronchial asthma and chronic obstructive pulmonary diseaseClinical & Experimental Allergy, 1998